The University of St Andrews chooses NanoSight NTA system for exosomes characterization

Salisbury, UK, 10th May 2011: NanoSight, world-leading manufacturers of unique nanoparticle characterization technology reports that the School of Medicine at the University of St Andrews is using nanoparticle tracking analysis, NTA, to characterize exosome behaviour.

Dr Simon Powis and his colleagues at the University of St Andrews are working to understand how a set of molecules involved in the immune system’s defence against intracellular pathogens function. These molecules are called major histocompatibility complex (MHC) class I molecules, and they are expressed on almost every cell in the body. Their relevance to medicine is most commonly known because they are one of the key sets of genes that have to be closely matched when an organ transplant is made, otherwise the transplant can be rejected.

Dr Simon Powis with his NanoSight LM10 system to study exosome behaviour

It is now known that their precise role in the normal immune system is to bind small fragments of degraded viral proteins which they display to T lymphocytes of the immune system. This allows the specific detection of ‘foreign’ proteins, i.e. from potential pathogens, and allows the immune system to specifically detect and kill infected cells, whilst leaving a neighbouring uninfected cell alone. In addition, there is one fascinating autoimmune disease closely associated with a particular type of MHC class I molecule. Over 90% of patients with a type of inflammatory arthritis called ankylosing spondylitis which affects the spine, expresses one specific type of MHC class I molecule called HLA-B27. The link between this arthritic condition and HLA-B27 has been known for almost 40 years, but the disease mechanism and how HLA-B27 is involved is yet to be understood.

Whilst the Powis group were studying MHC class I molecules expressed on exosomes, it was discovered that they can express a novel type of structure. The tail region of the MHC class I molecule, which sits inside the exosome, can frequently form a disulfide-bond linkage to another MHC class I molecule, thus bringing two molecules closely together in a dimeric structure. This normally does not happen on cells because the cytoplasm has a reducing environment, preventing disulfide bonds from forming. However, in exosomes the capacity to maintain a reducing environment seems to have been lost. The group is now studying whether cells of the immune system see these MHC class I dimers structures on exosomes and respond to them. Another key question is what peptides are found bound to MHC class I molecules on exosomes. The exosome production pathway is not the normal route for MHC class I molecules to get to the cell surface, so the possibility that different peptides are found in this subset of exosomal MHC class I molecules is a real possibility. To be able to study these exosomes from a variety of immune cells, it is necessary to detect their presence and size in cultures. This is the reason for the team choosing the NanoSight NTA approach with the LM10 system.

Prior to using NanoSight, flow cytometry had proved a valuable tool in the preliminary characterisation of the exosomes released by immune cells. Dr Powis says “The NanoSight approach allows a more accurate determination of size and relative concentration both before and after purification. This allows us to monitor the release of exosomes in the range 30-150nm after activation with a variety of immune stimuli relevant to both normal and aberrant immune responses in a way not previously visible with flow cytometry.”

To learn more about nanoparticle characterization using Nanoparticle Tracking Analysis, NTA, please visit the company website and register for the latest issue of NanoTrail, the company’s electronic newsletter.

About NanoSight
NanoSight delivers the world’s most versatile and proven multi-parameter nanoparticle analysis in a single instrument.

NanoSight visualizes, measures and characterizes virtually all nanoparticles. Particle size, concentration, Zeta potential and aggregation can all be analyzed while a fluorescence mode provides speciation (differentiation) of labeled particles. NanoSight presents real time monitoring of the subtle changes in the characteristics of particle populations with all of these analyses uniquely confirmed by visual validation.

NanoSight’s “Nanoparticle Tracking Analysis” (NTA) detects and visualizes populations of nanoparticles in liquids down to 10nm, dependent on material, and measures the size of each particle from direct observations of diffusion. This particle-by-particle methodology goes beyond traditional light scattering and other ensemble techniques in providing high-resolution particle size distributions. Additionally, NanoSight measures concentration and validates data with information-rich video files of the particles moving under Brownian motion.

NanoSight’s comprehensive characterization matches the demands of complex biological systems, hence its wide application in development of drug delivery systems, of viral vaccines, in nanotoxicology and in biodiagnostics. This real-time data gives insight into the kinetics of protein aggregation and other time-dependent phenomena in a qualitative and quantitative manner.

NanoSight has a growing role in biodiagnostics, being proven in detection and speciation of nanovesicles (exosomes) and microvesicles. As functionalized nanoparticles increasingly fulfill their potential in biodiagnostics, NanoSight is ever more the analytical platform of choice.

NanoSight demonstrates worldwide success through rapid adoption of NTA, having installed more than 250 systems worldwide with users including BASF, GlaxoSmithKline, Merck, Novartis, Pfizer, Proctor and Gamble, Roche and Unilever together with the most eminent universities and research institutes. In addition to this user base more than 150 third party papers citing NanoSight results consolidate NanoSight’s leadership position in nanoparticle characterization. For more information, visit the NanoSight website www.nanosight.com

For further information
Please contact NanoSight direct or their marketing agency, NetDyaLog Limited:

NanoSight Limited
Minton Park
London Road
Amesbury SP4 7RT
T +44 (0) 1980 676060
F +44 (0) 1980 624703
www.nanosight.com
jeremy.warren@nanosight.com

NetDyaLog Limited
39 de Bohun Court
Saffron Walden
Essex CB10 2BA
T +44 (0) 1799 521881
M +44 (0) 7843 012997
www.netdyalog.com
jezz@netdyalog.com